The Smallpox Vaccine stands as a historic triumph in the field of vaccinology, marking one of humanity's most significant victories over infectious disease. Developed in the late 18th century by Edward Jenner, the smallpox vaccine was the first successful vaccine ever created, paving the way for the eradication of smallpox, one of the deadliest diseases in human history. The smallpox vaccine is derived from the vaccinia virus, a related virus that belongs to the same family as the smallpox virus, Variola. Jenner discovered that individuals who had been infected with cowpox, a mild disease similar to smallpox, appeared to be protected against smallpox. Drawing on this observation, Jenner developed a vaccine by inoculating individuals with material from cowpox lesions, leading to immunity against smallpox.
The success of the smallpox vaccine revolutionized public health practices and laid the foundation for the development of other vaccines. Through widespread vaccination campaigns, smallpox was eventually eradicated from the world in 1980, making it the first and only human disease to be eradicated through vaccination. The smallpox vaccine's impact on global health cannot be overstated. Prior to its development, smallpox epidemics ravaged populations around the world, causing millions of deaths and leaving survivors scarred and disfigured. The vaccine's introduction led to a dramatic decline in smallpox cases and mortality rates, saving countless lives and sparing future generations from the devastation wrought by this deadly disease.
Although smallpox vaccination is no longer routinely administered due to the eradication of the disease, stocks of the vaccine are maintained for use in the event of a bioterrorism threat or outbreak. The smallpox vaccine continues to serve as a symbol of the power of vaccination to control and eliminate infectious diseases, inspiring ongoing efforts to develop vaccines against other deadly pathogens and protect global health.
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Prophylactic and Molecular Approaches for Mitigating Human Influenza A Viruses: i. Evaluating influenza Vaccine Effectiveness in the Older population ii. Down-regulation of influenza virus genes with novel siRNA-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a Novel Multi-component Vaccine to Address the Burden of Otitis Media in High-Risk Populations
Ayesha Zahid, Griffith University, Australia
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Immunosuppression in COVID-19 Patients and Emerging Fungal Infections: Vaccines, Diagnosis and Strategies to Treat Comorbidities
K R Aneja, Kurukshetra University, India
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Why is the vaccine life-threatening if people get a fever after a COVID-19 vaccination
Yacob Mathai, Marma Health Centre, India
Title : Barriers to polio eradication in South Asia: A systematic review
Awranoos Ahadi, Bolan Medical College, Pakistan